Cardiac-specific genetic inhibition of nuclear factor-κB prevents right ventricular hypertrophy induced by monocrotaline.

@article{Kumar2012CardiacspecificGI,
  title={Cardiac-specific genetic inhibition of nuclear factor-$\kappa$B prevents right ventricular hypertrophy induced by monocrotaline.},
  author={Sandeep Kumar and Chuanyu Wei and Candice Michelle Thomas and Il-Kwon Kim and Rachid Seqqat and Rajesh Kumar and Kenneth M. Baker and Walter Keith Jones and Sudhiranjan Gupta},
  journal={American journal of physiology. Heart and circulatory physiology},
  year={2012},
  volume={302 8},
  pages={
          H1655-66
        }
}
Uncontrolled pulmonary arterial hypertension (PAH) results in right ventricular (RV) hypertrophy (RVH), progressive RV failure, and low cardiac output leading to increased morbidity and mortality (McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. J Am Coll Cardiol 53: 1573-1619, 2009). Although the exact figures of its prevalence are difficult to obtain because of the diversity of identifiable causes… 

Figures and Tables from this paper

Inhibition of Nuclear Factor-&kgr;B in the Lungs Prevents Monocrotaline-Induced Pulmonary Hypertension in Mice

It is concluded that NF-&kgr;B regulates bone morphogenetic protein receptor 2–inhibitor of differentiation–Notch-3 axis genes and the subsequent endothelial cell apoptosis and endothelial-to-mesenchymal transition events in the lungs, providing new mechanistic information about MCT-induced PAH and right ventricular hypertrophy.

Right heart in pulmonary hypertension: from adaptation to failure

Therapies that target cell growth, cellular metabolism, oxidative stress, and myocyte regeneration are being tested preclinically and future research should include establishing novel RVF models based on existing models and characterizing alterations in cardiac excitation–contraction coupling during transition from adaptive RV to RVF.

Thymosin Beta 4 Protects Mice from Monocrotaline-Induced Pulmonary Hypertension and Right Ventricular Hypertrophy

In monocrotaline (MCT)-induced PH mouse model, it was showed that mice treated with Tβ4 significantly attenuated the systolic pressure and RVH, compared to the MCT treated mice, and data revealed for the first time that T β4 selectively targets Notch3-Col 3A-CTGF gene axis in preventing MCT-induced PH and RVh.

The Succinate Receptor GPR91 Is Involved in Pressure Overload-Induced Ventricular Hypertrophy

The findings indicate that succinate-GPR91 signaling may be involved in RVH via PI3K/Akt signaling in vivo and in vitro, and GPR91 may be a novel therapeutic target for treating pressure overload-induced RVH.

Chronic intermittent hypobaric hypoxia attenuates monocrotaline-induced pulmonary arterial hypertension via modulating inflammation and suppressing NF-κB/p38 pathway

Following CIHH treatments, apoptotic analysis showed a consistent decrease in T lymphocytes together with lower levels of CD4+ T cell subset as measured in spleen and blood samples, and CIHH treatment resulted in markedly reduced expression of TNF-α and IL-6 via the inhibition of NF-κB and p38 MAPK activity in rat lungs.

Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective

The accumulating body of evidence for inflammation and immunity in the pathogenesis of PH, as well as the use of inflammatory biomarkers and immunomodulatory therapy in PAH and CTEPH are summarized.

Inflammation in Right Ventricular Failure: Does It Matter?

The present review aims to summarize the current understanding of the pathogenesis of RV failure, focusing on inflammation, and attempts to formally emphasize the importance of inflammation and associated representative inflammatory molecules and cells in the primum movens and development of RV Failure in humans and in experimental models.

Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature

This review aims to comprehensively discuss and highlight these novel experimental approaches to confer, in the long‐term, greater health benefit in patients with PH.

References

SHOWING 1-10 OF 69 REFERENCES

Primary pulmonary hypertension.

For patients unresponsive during acute testing, continuous intravenous epoprostenol (prostacyclin, PGI2) improves haemodynamics and exercise tolerance, and prolongs survival in severe PPH (NYHA functional class III-IV).

Transgenic Gαq overexpression induces cardiac contractile failure in mice

The Gαq overexpressor exhibits a biochemical and physiologic phenotype resembling both the compensated and decompensated phases of human cardiac hypertrophy and suggests a common mechanism for their pathogenesis.

Suppressive Effect of Prostaglandin E1 on Pulmonary Hypertension Induced by Monocrotaline in Rats

It is suggested that PGE1 may be effective in the treatment of some forms of pulmonary hypertension in humans through the suppression of the Ca2+ influx.

Chronic pulmonary hypertension--the monocrotaline model and involvement of the hemostatic system.

  • A. E. SchultzeR. Roth
  • Medicine, Biology
    Journal of toxicology and environmental health. Part B, Critical reviews
  • 1998
Current evidence is consistent with involvement of platelet thrombosis of the pulmonary microvasculature and an altered fibrinolytic system, yet much remains to be learned about specific events and signals in the vascular pathogenesis.

Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension.

In this overview, the lung vascular histology of patients with unexplained pulmonary hypertension, scleroderma, or acquired immune deficiency syndrome (AIDS)-associated pulmonary hypertension is compared and the presence of inflammatory cells in plexiform lesions is demonstrated.

Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB.

The data suggest, for the first time, that inhibition of NF-kappaB using direct gene delivery of sh-p65 RNA results in regression of cardiac hypertrophy, and validate NF- kappaB as a therapeutic target to preventHypertrophy/HF.

Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1.

Intravenous administration of anti-MCAF/MCP-1 antibodies with MCT significantly decreased macrophage infiltration and eventually reduced the increases in RV/LV+S and RVSP, as well as medial thickening of pulmonary arterioles.

Pulmonary Arterial Hypertension: Evaluation and Management

Ongoing research promises to lead to a more comprehensive understanding of the genetics, etiology, and pathogenesis of pulmonary arterial hypertension, which may ultimately translate into more effective therapeutic options.
...